Pan-Biome Pharmaceuticals, a startup focused on age-related diseases and increasing human healthspan, reports positive results in a preclinical trial of colitis
25 avr. 2023 10h00 HE
|
Pan-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, April 25, 2023 (GLOBE NEWSWIRE) -- Pan-Biome Pharmaceuticals, Inc, a Vancouver based preclinical biopharmaceutical company focused on age-related diseases and extending...
BioAegis Therapeutics Announces Two Studies Exploring the Role of ‘Inflammation Regulator’ Gelsolin in Type 2 Diabetes
13 avr. 2023 14h03 HE
|
BioAegis Therapeutics
Gelsolin decreased microparticle-driven inflammation and mitigated activation of the NLRP3 inflammasome in type 2 diabetes. Low levels of gelsolin identified in individuals with type 2 diabetes...
Landmark Publication Underscores Robust Ability of CytoSorb to Reduce Cytokine Storm during Systemic Hyperinflammation
29 mars 2023 08h30 HE
|
CytoSorbents
PRINCETON, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
Cardiometabolic Health Congress Announces Spring Conference Focused on Inflammation and Cardiometabolic Disease
16 mars 2023 08h00 HE
|
Cardiometabolic Health Congress
Boca Raton, FL, March 16, 2023 (GLOBE NEWSWIRE) -- In line with its mission to deliver quality medical education to combat the spectrum of cardiometabolic diseases, CMHC joins forces with the...
AB2 Bio Completes Enrolment in Pivotal Phase 3 Trial of Tadekinig alfa to Treat Primary Monogenic IL-18 Driven HLH
07 mars 2023 03h00 HE
|
AB2 Bio Ltd
Topline pivotal Phase 3 results expected during second half of 2023Potential new treatment option in ultra-rare, life-threatening, primarily pediatric disease with no approved therapies Lausanne...
Evelo Biosciences Reports that EDP2939, its First Oral Extracellular Vesicle Product Candidate, Commenced Dosing in a Phase 2 Psoriasis Trial
27 févr. 2023 06h00 HE
|
Evelo Biosciences, Inc.
– Completed first blinded, placebo-controlled cohort in human volunteers with no safety or tolerability concerns – – Dosing in EDP2939 Phase 2 trial in patients with moderate psoriasis has been...
Two Nutrients Help Relieve Pain from Inflammation in Virtual Clinical Research Study
23 févr. 2023 11h11 HE
|
Life Extension
For Lauderdale, FL, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Is mild discomfort when walking, standing up or doing day-to-day activities a necessary evil of getting older? Indeed, these pangs, generally...
Insights on the Allergy Immunotherapies Global Market to 2028: Rising Awareness of Allergy Immunotherapies, Elevating Income Levels and Increasing Healthcare Expenditure Drives Growth
21 févr. 2023 13h18 HE
|
Research and Markets
Dublin, Feb. 21, 2023 (GLOBE NEWSWIRE) -- The "Allergy Immunotherapies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028" report has been added to ...
BioAegis Therapeutics Announces FDA Clearance of IND for its ‘Inflammation Regulator Protein,’ Gelsolin, for the Treatment of ARDS
26 janv. 2023 14h05 HE
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage company developing therapies for inflammatory diseases through a portfolio built around plasma...
BioMed X and AbbVie Extend Research Collaboration in the US
16 janv. 2023 13h00 HE
|
BioMed X Institute
HEIDELBERG, Germany, Jan. 16, 2023 (GLOBE NEWSWIRE) -- BioMed X, an independent German biomedical research institute, announced today the extension of its ongoing research collaboration with AbbVie....